Phase I , MTD, Pharmacokinetic, Safety/Tolerability, Efficacy of IOP Injection for MRI in Healthy Subjects

Summary

Study Objectives Primary: To determine MTD and dose limiting toxicities (DLTs) of IOP magnetic resonance imaging (MRI) contrast agent in healthy subjects. Secondary: 1. To characterize the pharmacokinetic profiles of IOP MRI contrast agent in healthy subjects. 2. To evaluate safety/tolerability profiles of IOP MRI contrast agent in healthy subjects. 3. To explore efficacy profiles of IOP MRI contrast agent for liver organ in healthy subjects.

Timeline

Start

2016-02

Primary completion

2016-12

Completion

2017-12

Drugs

Indications

No indication recorded.